Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Dec 12, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Partner Navigation Intervention Study is a research trial aimed at finding out how effective a new support program can be in helping young people who inject drugs to start treatment for hepatitis C, a viral infection that can affect the liver. This study is looking for participants who are aged 16 to 30, have injected drugs in the past month, and have a partner with whom they currently inject drugs. If you or someone you know fits this description and has been diagnosed with hepatitis C at a community clinic, you may be eligible to take part in this important study.
Participants in this trial can expect to receive support from a "partner navigator," who will help guide them through the process of starting treatment for hepatitis C. The goal is to make it easier for individuals to access the care they need. The study is currently recruiting participants, and it’s a great opportunity for those affected by hepatitis C to get both support and potential treatment options. If you’re interested or want to know more, please reach out for further information!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Self report injecting drugs in the past month
- • Self report a primary injecting partner (currently inject drugs together)
- • HCV infection identified at partnering community-based clinical site
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Trial Officials
Meghan D Morris, MPH, PhD
Principal Investigator
University of California, San Francisco
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported